Company Overview
Intelligent Bio Solutions Inc. operates within the healthcare sector, specifically focusing on the medical devices industry to provide non-invasive testing and screening solutions across Asia Pacific, the United States, the United Kingdom, and international markets. The company specializes in the development and delivery of intelligent fingerprinting drug screening systems, utilizing a platform designed to streamline diagnostic processes for its global clientele. Currently, Intelligent Bio Solutions Inc. maintains a market capitalization of $6.44M and employs a workforce of 53 individuals to support its operations. With annual revenue reported at $3.58M over the trailing twelve months, the company's financial scale indicates it is a small-cap entity with limited revenue generation relative to its peer group in the medical device sector.
Financial Health
The company reported revenue of $3.58M for the trailing twelve months, yet it recorded a net income of $-11,294,226, revealing a significant gap between top-line generation and profitability that highlights a highly leveraged cost structure or substantial one-time expenses. This negative net income is further reflected in an EBITDA of $-9,836,561, suggesting that operating activities are not yet generating positive cash conversion before financing costs. Free cash flow stands at $-14,541,733, indicating that the company is consuming cash reserves rather than generating liquidity, which constrains its financial flexibility and ability to fund expansion without external capital. Margin analysis shows a gross margin of 46.2%, which suggests a reasonable cost of goods relative to sales, but this is counterbalanced by an operating margin of -290.9% and a profit margin of 0.0%, indicating severe operational inefficiencies or high overhead costs that prevent profitability. On the balance sheet, the company holds $740,371 in cash against $1.92M in debt, resulting in a debt-to-equity ratio of 17.67, which characterizes the capital structure as highly leveraged and sensitive to interest rate fluctuations. The current ratio is 2.38, implying that the company possesses sufficient short-term assets to cover its short-term liabilities, though this liquidity buffer is diminished by the negative operating performance. Return on Equity is -150.2% and Return on Assets is -51.2%, metrics that reveal that management has not yet achieved effectiveness in generating returns on the capital invested by shareholders or utilized in its asset base.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is 9.20, a discrepancy that implies the market prices the stock based on anticipated future earnings recovery rather than historical profitability. The price-to-book ratio is 0.36, indicating that the market values the company at significantly less than its net asset value, suggesting a deep discount to the book value of its underlying assets. Additionally, the price-to-sales ratio is 1.80 and the EV/EBITDA is -0.62, metrics that suggest the company is valued based on sales multiples rather than earnings power, often seen in growth-stage or distressed firms. The stock has a 52-week high of $24.90 and a 52-week low of $3.22, placing the current trading price well below the high and significantly above the low, reflecting high volatility in recent trading sessions. The beta value is 4.63, which indicates that the stock's price volatility is nearly five times greater than that of the broader market, exposing investors to substantial price swings during periods of market movement.
Growth & Income
Revenue growth year-over-year is 47.6%, demonstrating a strong expansion in top-line sales, whereas earnings growth is N/A due to the company's negative net income, implying that sales growth has not yet translated into profitable earnings expansion. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing cash to shareholders, the firm retains all earnings to fund operations and growth initiatives. Since the company is not a dividend payer, the entire growth profile is driven by the aggressive revenue expansion of 47.6% rather than income generation through dividends. Overall, the company presents a high-growth, non-income profile characterized by significant top-line expansion that has not yet resulted in profitability or shareholder distributions.